Today, Volume 11, Issue 3 of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) was published online and included Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study
“The Alpha-1 Foundation was excited to work with Inhibrx on this Phase 1 Study and recruit from the Alpha-1 Research Registry. INBRX-101 allows patients to sustain AAT levels for 3-4 weeks between doses than the weekly infusions that are currently available, resulting in less frequent dosing and possible improvement in treatment compliance. As a recombinant protein, it is not reliant on human blood donations and any risk associated with the transmission of bloodborne pathogens. The Foundation is working on many fronts to facilitate the success of this trial and other clinical trials to realize their potential benefit for the patient.”
Scott Santarella, President & CEO, Alpha-1 Foundation
